Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 9c
Get Alerts ALLO Hot Sheet
Join SI Premium – FREE
Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.52), $0.09 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $86 thousand versus the consensus estimate of $8.33 thousand.
For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
- Live Oak Bancshares, Inc. (LOB) Misses Q1 EPS by 11c
- Towne Bank (TOWN) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!